Hospital Beatriz Ângelo

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis5 trials
• Metastatic breast cancer4 trials
• Alzheimer disease3 trials
• Crohn's disease2 trials
• IgA nephropathy2 trials
• Lung cancer2 trials
• Bladder cancer1 trial
• Frontotemporal dementia1 trial
• Ovarian cancer1 trial
• Schizophrenia1 trial
• Ulcerative colitis1 trial

Phase

• Phase 318 trials
• Phase 21 trial
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed14 trials
• Active, not recruiting6 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• Biogen2 trials
• Janssen Research & Development, LLC2 trials
• Novartis Pharmaceuticals2 trials
• Novo Nordisk A/S2 trials
• and 11 more

Running trials

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Roll-over Study to Allow Continued Access to Ribociclib

  NCT05161195· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  The CROCO Study: CROhn's Disease COhort Study

  NCT05420233· GLSMED Learning Health S.A.· Source

• Active, not recruiting

  Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

  NCT04241185· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

  NCT03958877· Phase 3· Biogen· Source

• Active, not recruiting

  An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS

  2023-507906-15-00· Phase 3· Novartis Pharma AG· Source

• Active, not recruiting

  Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

  NCT02947685· Phase 3· Alliance Foundation Trials, LLC.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source

• Completed

  Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer

  NCT05207709· Phase 3· Solti Group· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

  NCT05248646· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Epidemiological Study in FRONtoTemporal Dementia

  NCT05075187· CENTOGENE GmbH Rostock· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

  NCT04544436· Phase 3· Hoffmann-La Roche· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Completed

  A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

  NCT03762850· Phase 3· Travere Therapeutics, Inc.· Source

• Completed

  Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease

  2024-511553-22-00· Phase 3· Celgene International II SARL· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Hoffmann-La Roche· Source